Brought to you by 
Danaher takes over Beckman Coulter in deal worth $6.8bn
11 Feb 2011
Executive Summary
In its latest deal that adds more instrumentation offerings, Danaher Corp. (testing and analytical systems, dental technologies, and diagnostics) is acquiring public biomedical testing company Beckman Coulter Inc. for $83.50 per share (a 47% premium to the ten-day average prior to December 9, 2010, when the takeover was rumored). Including Beckman’s 70.9mm shares outstanding, plus the assumption of debt and net cash, the transaction is valued at $6.8bn.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Services
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Hematology, Coagulation
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Danaher takes over Beckman Coulter in deal worth $6.8bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice